91224-37-2
Chemical Structure
Spantide I
- CAS No.: 91224-37-2
- Formula:C75H108N20O13
- Molecular Weight:1497.79
IUPAC Name: (S)-2-((S)-1-(D-arginyl-L-prolyl-L-lysyl)pyrrolidine-2-carboxamido)-N1-((S)-5-amino-1-(((R)-1-(((S)-1-(((R)-1-(((S)-1-(((S)-1-amino-4-methyl-1-oxopentan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)amino)-1-oxo-3-phenylp
InChIKey: SAPCBHPQLCZCDV-CHPWDEGWSA-N
SMILES: CC(C)C[C@@H](C(N)=O)NC([C@H](CC(C)C)NC([C@@H](CC1=CNC2=CC=CC=C12)NC([C@H](CC3=CC=CC=C3)NC([C@H](NC([C@H](CCC(N)=O)NC([C@H](CCC(N)=O)NC([C@H]4N(CCC4)C([C@H](CCCCN)NC([C@H]5N(CCC5)C([C@H](N)CCCNC(N)=N)=O)=O)=O)=O)=O)=O)CC6=CNC7=CC=CC=C67)=O)=O)=O)=O
Biological Activity: Spantide I, a substance P analog, is a selective NK1 receptor antagonist, with Ki values of 230 nM and 8150 nM for NK1 and NK2 receptor, respectively. Spantide I provides an approach to reduce type 1 and enhance the type 2 cytokine IL-10 in the infected cornea, leading to a significant reduction in corneal perforation[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Spantide I | 99.64% | Spantide I, a substance P analog, is a selective NK1 receptor antagonist, with Ki values of 230 nM and 8150 nM for NK1 and NK2 receptor, respectively. Spantide I provides an approach to reduce type 1 and enhance the type 2 cytokine IL-10 in the infected cornea, leading to a significant reduction in corneal perforation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. J C Beaujouan, et al. Higher potency of RP 67580, in the mouse and the rat compared with other nonpeptide and peptide tachykinin NK1 antagonists. Br J Pharmacol. 1993 Mar;108(3):793-800. [Content Brief]
- [2]. M Zubrzycka, et al. Comparison of antagonistic properties of substance P analogs, spantide I, II and III, on evoked tongue jerks in rats. Endocr Regul. 2000 Mar;34(1):13-8. [Content Brief]
- [3]. Linda D Hazlett, et al. Spantide I decreases type I cytokines, enhances IL-10, and reduces corneal perforation in susceptible mice after Pseudomonas aeruginosa infection. Invest Ophthalmol Vis Sci. 2007 Feb;48(2):797-807. [Content Brief]
Keywords
